Table 5.

Associations between haplotyes of CYP19A1 and endometrial cancer risk

HaplotypesAll subjects
Premenopausal women
Postmenopausal women
CasesControlsOR* (95% CI)CasesControlsOR* (95% CI)CasesControlsOR* (95% CI)
GCACA5885501.02562111.03323391.0
TCATC2963670.76 (0.62-0.92)1261340.79 (0.58-1.07)1702330.75 (0.58-0.96)
GCCTA3733311.05 (0.87-1.27)1611241.07 (0.79-1.44)2122071.05 (0.82-1.34)
TTCTA1931661.09 (0.89-1.38)84621.11 (0.76-1.62)1091041.07 (0.79-1.46)
GCATC1501680.83 (0.65-1.07)61800.64 (0.44-0.93)89881.04 (0.74-1.44)
TCACA1831730.99 (0.78-1.26)89671.06 (0.74-1.54)941060.91 (0.66-1.24)
Others3013150.90 (0.74-1.09)1251140.90 (0.66-1.23)1762010.89 (0.69-1.15)
Ptrend0.750.640.88
  • NOTE: The number of participants does not add up to the total number of women because of missing data on genotypes for some participants.

  • * Unconditional logistic model adjusted for age.

  • In the order of SNP 1-2-3-4-5 based on their chromosome position (SNP1, rs1065779; SNP2, rs700519; SNP3, rs28566535; SNP4, rs752760; and SNP5, rs1870050).